ALK and peripheral neuropathy: Despite being generally well tolerated, lorlatinib has a unique and challenging safety profile compared with other ALK-TKIs that is characterized by hyperlipidemia, cognitive effects, mood effects, oedema, and peripheral neuropathy which are documented by both FDA and EMA.